Inventor · disambiguated record
Zeling Cai
Also filed as: CAI ZELING
25 granted patents·16 pending applications·292 citations·filing 1996–2023
96Inventor score
Files withCAI ZELING11SCRIPPS RESEARCH INST10SHANGHAI CELGEN BIO PHARMACEUTICAL CO LTD6SHANGHAI KANDA BIOTECHNOLOGY CO LTD4DING BANG2
Top patents by PatentIndex Score
41 records- 0194US7842501B2Ex-vivo priming for generating cytotoxic T lymphocytes specific for non-tumor antigens to treat autoimmune and allergic diseaseORTHO MCNEIL PHARM INC·Filed 2007·Granted Nov 30, 2010·25 cites·1 claims
- 0292US6255073B1Antigen presenting system and methods for activation of T-cellsSCRIPPS RESEARCH INST·Filed 1998·Granted Jul 3, 2001·79 cites·4 claims
- 0390US8084256B2Ex-vivo priming for generating cytotoxic T lymphocytes specific for non-tumor antigens to treat autoimmune and allergic diseaseCAI ZELING·Filed 2010·Granted Dec 27, 2011·10 cites·1 claims
- 0488US8124408B2Preparation of inactivated artificial antigen presenting cells and their use in cell therapiesCAI ZELING·Filed 2007·Granted Feb 28, 2012·15 cites·24 claims
- 0588US7993638B2Cancer treatment combining lymphodepleting agent with CTLs and cytokinesJANSSEN PHARMACEUTICA NV·Filed 2007·Granted Aug 9, 2011·13 cites·7 claims
- 0688US6828150B2Antigen presenting system and methods for activation of T-cellsSCRIPPS RESEARCH INST·Filed 2002·Granted Dec 7, 2004·11 cites·10 claims
- 0787US6225042B1Antigen presenting system and methods for activation of T-cellsSCRIPPS RESEARCH INST·Filed 1998·Granted May 1, 2001·55 cites·5 claims
- 0883US6362001B1Method for producing a synthetic antigen presenting transformed Drosophila cellSCRIPPS RESEARCH INST·Filed 1998·Granted Mar 26, 2002·45 cites·2 claims
- 0981US8357533B2Preparation of inactivated artificial antigen presenting cells and their use in cell therapiesJANSSEN PHARMACEUTICA NV·Filed 2012·Granted Jan 22, 2013·5 cites·11 claims
- 1079US8232101B2Identification of antigenic peptides from multiple myeloma cellsCAI ZELING·Filed 2011·Granted Jul 31, 2012·2 cites·7 claims
- 1176US2025333507A1Fusion protein of anti-tigit antibody and il2 or variant thereof, and application thereofSHANGHAI CELGEN BIO PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1275US6461867B1Synthetic antigen presenting matrixSCRIPPS RESEARCH INST·Filed 1996·Granted Oct 8, 2002·22 cites·3 claims
- 1373US8075895B2Identification of antigenic peptides from multiple myeloma cellsCAI ZELING·Filed 2009·Granted Dec 13, 2011·1 cites·3 claims
- 1471US11021538B2Bispecific coupled antibody, preparation method and application thereofSHANGHAI KANDA BIOTECHNOLOGY CO LTD·Filed 2018·Granted Jun 1, 2021·1 cites·5 claims
- 1571US10562954B2Fusion protein inhibiting TACI-BAFF complex formation and preparation method therefor and use thereofSHANGHAI KANDA BIOTECHNOLOGY CO LTD·Filed 2014·Granted Feb 18, 2020·3 cites·17 claims
- 1671US2024400680A1Fusion protein of anti-tigit antibody and il2 or variant thereof and application thereofSHANGHAI CELGEN BIO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1771US2024417462A1Monoclonal antibody targeting tigitSHANGHAI CELGEN BIO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1867US2005152916A1Antigen presenting system and methods for activation of T-cellsSCRIPPS RESEARCH INST·Filed 2004·Application pending·0 cites
- 1962US2007098734A1Ex-vivo priming for generating cytotoxic T lymphocytes specific for non-tumor antigens to treat autoimmune and allergic diseaseORTHO MCNEIL PHARMACEUTICAL CO·Filed 2006·Application pending·0 cites
- 2061US2025136654A1Anti-her-2 antibody-granulocyte regulatory factor fusion protein, preparation method therefor and application thereofSHANGHAI CELGEN BIO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2160US8323655B2Identification of antigenic peptides from multiple myeloma cellsCAI ZELING·Filed 2011·Granted Dec 4, 2012·0 cites·3 claims
- 2260US2024150432A1Fusion protein of tnfr2 and april baff receptorSHANGHAI CELGEN BIO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2360US2003072796A1Synthetic antigen presenting matrix with liposome supportSCRIPPS RESEARCH INST·Filed 2002·Application pending·0 cites
- 2460US2003077318A1Synthetic antigen presenting matrixSCRIPPS RESEARCH INST·Filed 2002·Application pending·0 cites
- 2559US8323965B2Identification of antigenic peptides from multiple myeloma cellsCAI ZELING·Filed 2011·Granted Dec 4, 2012·0 cites·1 claims
- 2659US8133728B2Ex-vivo priming for generating cytotoxic T lymphocytes specific for non-tumor antigens to treat autoimmune and allergic diseaseCAI ZELING·Filed 2010·Granted Mar 13, 2012·0 cites·1 claims
- 2759US8133726B2Ex-vivo priming for generating cytotoxic T lymphocytes specific for non-tumor antigens to treat autoimmune and allergic diseaseCAI ZELING·Filed 2010·Granted Mar 13, 2012·0 cites·1 claims
- 2859US8133972B2IgE antigenic peptidesCAI ZELING·Filed 2010·Granted Mar 13, 2012·0 cites·1 claims
- 2959US8084253B2Ex-vivo priming for generating cytotoxic T lymphocytes specific for non-tumor antigens to treat autoimmune and allergic diseaseCAI ZELING·Filed 2010·Granted Dec 27, 2011·0 cites·1 claims
- 3059US2024392024A1Anti-tnfr2 monoclonal antibody and application thereofSHANGHAI CELGEN BIO PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 3158US8106153B2Ex-vivo priming for generating cytotoxic T lymphocytes specific for non-tumor antigens to treat autoimmune and allergic diseaseCAI ZELING·Filed 2010·Granted Jan 31, 2012·0 cites·1 claims
- 3256US2024317889A1Anti-her-2 antibody-chemokine fusion protein, preparation method therefor and application thereofSHANGHAI KANDA BIOTECHNOLOGY CO LTD·Filed 2021·Application pending·0 cites
- 3354US6251627B1Antigen presenting system and methods for activation of T-cellsSCRIPPS RESEARCH INST·Filed 1998·Granted Jun 26, 2001·5 cites·5 claims
- 3454US2003077708A1Antigen presenting system and methods for activation of T-cellsSCRIPPS RESEARCH INST·Filed 2002·Application pending·0 cites
- 3550US11208483B2CTLA-4 antibodies and uses thereofSHANGHAI KANDA BIOTECHNOLOGY CO LTD·Filed 2015·Granted Dec 28, 2021·0 cites·20 claims
- 3649US7811816B2Isolated CD8 +T lymphocytes specifically cytotoxic for a disease causing target cellORTHO MCNEIL PHARMAEUTICAL INC·Filed 2002·Granted Oct 12, 2010·0 cites·1 claims
- 3749US2006234310A1Enriched antigen-specific T-cells and related therapeutic and prophylactic compositions and methodsORTHO MCNEIL PHARM INC·Filed 2006·Application pending·0 cites
- 3847US2023203204A1Fusion protein, preparation method therefor and use thereofDING BANG·Filed 2021·Application pending·0 cites
- 3944US2002049302A1Enriched antigen-specific-cells and related therapeutic and prophylactic compositions and methodsFiled 2000·Application pending·0 cites
- 4043US12344646B2Antibody-TNF α fusion protein and its preparation and applicationsDING BANG·Filed 2018·Granted Jul 1, 2025·0 cites·4 claims
- 4134US2019062402A1Acvr1-fc fusion protein, preparation method therefor, and application thereofSHANGHAI KANDA BIOTECHNOLOGY·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Zeling Cai files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →